Overview

Photodynamic Therapy Using Aminolevulinic Acid in Treating Patients With Oral Leukoplakia

Status:
Terminated
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of photodynamic therapy using aminolevulinic acid in treating patients with oral leukoplakia. Photodynamic therapy uses a drug, such as aminolevulinic acid, that becomes active when it is exposed to a certain kind of light. When the drug is active, abnormal cells are killed. Photodynamic therapy using aminolevulinic acid may be effective against oral leukoplakia.
Phase:
Phase 1
Details
Lead Sponsor:
National Cancer Institute (NCI)
Treatments:
Aminolevulinic Acid